Intellia Therapeutics, Inc. (NTLA) financial statements (2021 and earlier)

Company profile

Business Address 40 ERIE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28059341273
Cash and cash equivalents5759341273
Short-term investments223   
Receivables58106
Other undisclosed current assets525942
Total current assets:289325355281
Noncurrent Assets
Operating lease, right-of-use asset19
Property, plant and equipment18171511
Long-term investments and receivables5   
Long-term investments5   
Other noncurrent assets3567
Total noncurrent assets:45222118
TOTAL ASSETS:334347376299
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17131011
Accounts payable4325
Accrued liabilities131186
Deferred revenue13
Debt6   
Deferred revenue and credits2120
Contract with customer, liability27
Total current liabilities:36413131
Noncurrent Liabilities
Long-term debt and lease obligation13   
Operating lease, liability13
Liabilities, other than long-term debt16294458
Deferred revenue and credits4458
Deferred revenue16
Contract with customer, liability29
Other liabilities 000
Total noncurrent liabilities:29294458
Total liabilities:64697689
Stockholders' equity
Stockholders' equity attributable to parent270278301210
Common stock0000
Additional paid in capital570479422263
Accumulated other comprehensive income (loss)0(0)  
Accumulated deficit(301)(201)(121)(54)
Total stockholders' equity:270278301210
TOTAL LIABILITIES AND EQUITY:334347376299

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net2616
Gross profit:43302616
Operating expenses(149)(121)(96)(49)
Operating loss:(106)(91)(70)(32)
Nonoperating income
(Investment Income, Nonoperating)
7621
Net loss available to common stockholders, diluted:(100)(85)(68)(32)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(100)(85)(68)(32)
Comprehensive loss:(100)(85)(68)(32)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)  
Comprehensive loss, net of tax, attributable to parent:(99)(85)(68)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: